Company
Thermo Fisher Scientific Inc TMO
Tracked across 13 disclosed holders on Protégé.
10 tracked investors, latest 13F quarter ending 30 Sep 2026 · 2 members of Congress · 1 executive · latest filing 20 Oct 2026
Held by these investors
| Investor | Weight in portfolio | Value (13F) | Quarter ending |
|---|---|---|---|
| Veritas Asset Management | 8.0% | $442.6M | 2026-06-30 |
| Farallon Capital Management | 3.1% | $526.0M | 2026-06-30 |
| Andreas Halvorsen | 2.8% | $971.3M | 2026-06-30 |
| Egerton Capital | 1.4% | $133.8M | 2026-09-30 |
| Woodline Partners | 0.5% | $158.6M | 2026-06-30 |
| Alyeska Investment Group | 0.5% | $188.5M | 2026-06-30 |
| Winton Capital Management | 0.5% | $14.2M | 2026-06-30 |
| Balyasny Asset Management | 0.4% | $225.4M | 2026-06-30 |
| Sculptor Capital Management | 0.3% | $20.6M | 2026-06-30 |
| Element Capital Management | 0.1% | $2.0M | 2026-06-30 |
Members of Congress who disclosed trades
| Politician | Disclosed activity | Est. net |
|---|---|---|
| Michael Rulli | 0 buys / 1 sell | -$8K |
| Dwight Evans | 0 buys / 1 sell | -$8K |
Company executives who disclosed trades
| Executive | Disclosed activity | Net |
|---|---|---|
| Marc Casper | 0 buys / 32 sells | -$128.9M |
Sources: SEC EDGAR (Form 13F-HR and Form 4) and the official House and Senate STOCK Act disclosures. Filings are quarterly or delayed, so current holdings may differ. Weights are each holder's own portfolio share, not a share of the company.